Why Attend?

Neuroendocrine tumor (NET) disease is both rare and complex. About 15,000 new patients are diagnosed each year in the U.S. – which means that many medical professionals will only encounter neuroendocrine tumors a few times in their careers. With new research, technologies and practices emerging, the landscape
of NET treatment is rapidly changing.
  • The support we provide to medical professionals is crucial to successful treatment and management of NET disease patients. This yearly conference is the premier opportunity to share in the growing knowledge of NET disease treatment – and interact with medical professionals on the front lines of the disease.
  • Over the course of three days, you and your peers will be privy to the latest in NET research, diagnostic techniques, treatment options and best patient practices.
  • This highly interactive gathering will also grant you the ability to share your unique NET insights, research and experiences.
This website contains information on what you’ll find at the conference. With your participation, we will further the cause of NET disease management and treatment in an ever-changing medical world.


The NANETS Annual Symposium provides a forum for members of the professional neuroendocrine community to come together to discuss new diagnostic and therapeutic techniques, optimal multidisciplinary care, and the future of neuroendocrine tumor research.

We at NANETS are a society of over 400 multidisciplinary medical professionals committed to the support of our colleagues in treating NET patients, as well as furthering the cause of NET science and education in North America. NANETS supports the medical community via education, grants and scholarships to up-and-coming medical professionals responsible for advancing NET research and treatment. NANETS is also the only organization in the U.S. that offers a comprehensive education program focused on NET disease.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and the North American Neuroendocrine Tumor Society. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Objectives
After participating in the activity, the participant should be able to:
  • Interpret the strengths and weaknesses of recent and ongoing clinical trials (knowledge, competence).
  • Provide updated research on NETs diagnosis and treatment (knowledge).
  • Utilize Interventional Oncology and Nuclear Medicine where appropriate to improve patient care & outcomes (knowledge, competence, performance, patient outcomes).
  • Incorporate recently approved treatments into a patient treatment plan (knowledge, competence, performance, patient outcomes).
  • Formulate a comprehensive career plan for early career clinicians that integrates clinical, research, and practical aspects (knowledge, competence).
  • Apply recent findings in diagnostic and treatment of NETS to your practice and/or research (knowledge, competence).
  • Identify different modalities of diagnosis and treatment of NETS that will result in improved patient outcomes (knowledge).
  • Compare the strengths and weaknesses of the diagnosis and treatment options for Lung NETS (knowledge, competence).
  • Compare the strengths and weaknesses of the diagnosis and treatment options for GI/pNETS (knowledge, competence).
  • Compare the strengths and weaknesses of the diagnosis and treatment options for Pheochromocytoma & Paraganglioma (knowledge, competence).

Please contact NANETS at staff@nanets.net or (650) 762-6387 for more information.